Company: BLTE
Filing Date: 2025-09-08
Form Type: 6-K
Source: 0001104659-25-088050
Chunk: 0

Company: BELITE BIO, INC
Filing Date: 2025-09-08
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15b-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41359

Belite Bio, Inc

(Exact name of registrant as specified in its charter)

Not Applicable

(Translation of Registrant´s name into English)

12750 High Bluff Drive Suite 475,

San Diego, CA 92130

(Address of principal executive office)

Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-FxForm 40-F¨</div>

On September 8, 2025, Belite Bio, Inc (the “Company”)
issued a press release announcing its entry into certain securities purchase agreements (collectively, the “Securities Purchase
Agreements”) for a private placement in public equity financing (the “PIPE”) with leading healthcare investors (the
“Investors”) for the purchase and sale of 1,953,124 ordinary shares (the “Ordinary Shares”) of the Company, par
value US$0.0001 per share, and warrants to purchase 1,953,124 ordinary shares (the “Warrants”), at a purchase price of $64.00
per ordinary share and accompanying warrant. Each Warrant will be immediately exercisable, expire two years from the date of issuance
and have an exercise price of $76.80 per ordinary share. The gross proceeds of the PIPE are approximately $125 million, before deducting
placement agent fees and estimated offering expenses, as well as the potential for additional proceeds of approximately $150 million from
the exercise of the Warrants in full. The closing of the PIPE is expected to occur on or about September 9, 2025, subject to the
satisfaction of customary closing conditions (the “Closing Date”).

In connection with the PIPE, the Company and the Investors also entered
into a Registration Rights Agreement, dated as of September 8, 2025 (the “PIPE Registration Rights Agreement”),
providing for the registration for resale of the Ordinary Shares and the Company’s ordinary shares issuable upon exercise of the
Warrants. The